| Literature DB >> 30337816 |
Seung-Ho So1, Jong Won Lee1, Young-Sook Kim1, Sun Hee Hyun1, Chang-Kyun Han1.
Abstract
Ginseng has been traditionally used for several millennia in Asian countries, including Korea, China, and Japan, not only as a nourishing and tonifying agent but also as a therapeutic agent for a variety of diseases. In recent years, the various effects of red ginseng including immunity improvement, fatigue relief, memory improvement, blood circulation improvement, antioxidation, mitigation of menopausal women's symptoms, and anticancer an effect have been reported in clinical as well as basic research. Around the world, there is a trend of the rising consumption of health functional foods on the level of disease prevention along with increased interest in maintaining health because of population aging and the awareness of lifestyle diseases and chronic diseases. Red ginseng occupies an important position as a health functional food. But till now, international ginseng monographs including those of the World Health Organization have been based on data on white ginseng and have mentioned red ginseng only partly. Therefore, the red ginseng monograph is needed for component of red ginseng, functionality certified as a health functional food in the Korea Food and Drug Administration, major efficacy, action mechanism, and safety. The present red ginseng monograph will contribute to providing accurate information on red ginseng to agencies, businesses, and consumers both in South Korea and abroad.Entities:
Keywords: Health functional foods; Red ginseng; Red ginseng monograph
Year: 2018 PMID: 30337816 PMCID: PMC6190493 DOI: 10.1016/j.jgr.2018.05.002
Source DB: PubMed Journal: J Ginseng Res ISSN: 1226-8453 Impact factor: 6.060
Chemical structures of protopanaxadiol ginsenosides
| Type | Name | R1 (C-3) | R2 (C-20) |
|---|---|---|---|
| PPD (16 types) | Malnonylginsenoside Rb1 | -glu-glu-mal | -glu-glu- |
| Processed PPD (11 types) | Ginsenoside Rg3(S,R) | -glu-glu | -H |
glu, β-D-glucopyranosyl; mal, malonyl; ara(pyr), α-L-arabinopyranosyl; ara(fur), α-L-arabinofuranosyl; xyl, β-D-xylopyranosyl; ac, acetyl.
Chemical structures of protopanaxatriol-type and oleanane ginsenosides in red ginseng
| Type | Name | R1 (C-6) | R2 (C-20) |
|---|---|---|---|
| PPT (11 types) | Ginsenoside Re | -glu-rha | -glu |
| Processed PPT (3 types) | Ginsenoside Rg6 | -glu-rha | -H C20/21 double bond |
| Oleanane (2 types) | Ginsenoside Ro | -glucuronic acid-glu | -glu |
Glu, β-D-glucopyranosyl; rha, α-L-rhamnopyranosyl; xyl, β-D-xylopyranosyl.
Fig. 1Structural formulas of ginsenosides in red ginseng.
Fig. 2Generation of AFG in the red ginseng manufacturing process.
Fig. 3Generation of panaxytriol in the red ginseng manufacturing process.
Clinical data on red ginseng as a health functional food
| Samples | Design | Participants | Daily intake/intake duration | Results | References |
|---|---|---|---|---|---|
| Red ginseng powder | Random (no placebo) | 36 stomach cancer patients and 36 colorectal cancer patients | 4.5 g/6 months | The number of suppressor/cytotoxic cells, helper/inducer cells, NK cells, activated T cells, and B cells in the red ginseng group increased significantly in the red ginseng group | |
| Red ginseng extract | Random (no placebo) | 25 healthy individuals and 50 stomach cancer patients | 3 g/3 months | IL-2 and decrease rate of IL-10 were higher in the red ginseng group than in the control group | |
| Red ginseng extract | Random (no placebo) | 47 colorectal cancer patients | 3 g/3 months | IL-2, IL-8, and IL-10 activity was regulated in the red ginseng group than in the control group | |
| Red ginseng powder | Case study | 12,295 common cold patients | No dose | The ratio of those who caught the common cold was significantly lower in the red ginseng group. | |
| Red ginseng powder | Random, double-blind, placebo-controlled study | 24 male college students | 2.5-4 g/3 weeks | The red ginseng group significantly recovered CK and GOT activity and the range of motion of related joints | |
| Red ginseng extract | Placebo-controlled study | 24 students majoring in physical education | 3 g/8 weeks | Red ginseng intake did not affect the ability to perform aerobic or anaerobic exercise. O2 max, %VO2/VO2 max, and plasma BCAA and blood lactic acid tended to decrease. | |
| Red ginseng extract | Random, double-blind, placebo-controlled study | 18 healthy men | 60 g/11 days | The red ginseng group decreased in blood CK, IL-6, insulin, and blood glucose. | |
| Red ginseng extract | Random, double-blind, control study | 87 healthy men and women aged 20-59 years | 1.5 g, 3 g/8 weeks | Suppression of platelet aggregation due to ADP and collagen inducement No significant differences in blood coagulation (APTT and PT) and lipids | |
| Red ginseng products | Case study | 10 red ginseng product takers and 7 non-red ginseng product takers | 1.6 g/4-5 years | Collagen-induced platelet aggregation was suppressed in the red ginseng group—APTT was significantly extended in the red ginseng group. | |
| Red ginseng extract | Random, double-blind, control study | 15 healthy men | 200 mg/8 weeks | The red ginseng group exhibited significant improvements in or on the 3-back task and the Corsi block-tapping test. There were significant improvements in social relationships in the WHO Quality of Life-BREF as well. | |
| Red ginseng powder | Random, placebo-controlled, open-label (open study) | 31 Alzheimer's disease patients aged 50 years or above taking medication | 4.5 g or 9.0 g/12 weeks | The high-dose red ginseng group improved significantly on both the ADAS and the CDR. | |
| Red ginseng powder | Double-blind, random, placebo-controlled | 15 healthy, smoking male students aged 19-31 years (smoked 20 cigarettes/day or above in the past 2 years) | 1.8 g/4 weeks | Time-dependent decrease in the 8-OHdG concentration in smokers who had taken red ginseng was clearly confirmed. Red ginseng intake significantly decreased the carbonyl content (protein oxidation) of peripheral hemoglobin in comparison with the baseline. | |
| Red ginseng extract | Random, placebo-controlled | 40 male college students | 2.7 g/3 months | Red ginseng group exhibited significant effects in SOD, GPX, and MDA | |
| Red ginseng powder | Random, double-blind, placebo-controlled | 57 healthy drinking and smoking adults aged 20-65 years | 3 g or 6 g/8 weeks | DNA damages, SOD, GPX, CAT, blood oxidized LDL, and urine 8-epi PGF2α improved in red ginseng groups | |
| Red ginseng powder | Random, double-blind, placebo-controlled | 82 menopausal women aged 45-60 years | 3 g/12 weeks | SOD activity increased significantly in the red ginseng group. No effect on GPX, 8-OHdG, IL-6, AST, ALT, and γ-GTP | |
| Red ginseng powder | Random, double-blind, placebo-controlled | 63 menopausal women aged 45-60 years | 3 g/12 weeks | The red ginseng group exhibited significant improvements in Kupperman and menopause rating index and total and LDL-cholesterol. No difference in the estradiol (E2) concentration | |
| Red ginseng extract | Random, double-blind, placebo-controlled | 26 menopausal women with hot flashes | 0.9 g/8 weeks | The frequency of the occurrence of hot flash symptoms decreased significantly in the red ginseng group. | |
| Red ginseng powder | Comparison before and after intake | 83 menopausal women | 6 g/8 weeks | Follicle-stimulating hormones decreased and E2, red blood cell deformability, and ATP increased. | |
| Red ginseng powder | - | 17 menopausal women | 6 g/3 months | Vital energy deficiency (KI-deficiency), blood stasis ( t-PAI-1 decreased significantly after red ginseng intake. | |
| Red ginseng powder | - | Women with estrogen levels of 10 pg/ml or below | 6 g/30 days | The anxiety (A)-state in the Cornel Medical Index and the State-Trait Anxiety Inventory was found to recover to levels of the menopausal women's group without climacteric syndromes and the cortisol/DHEA-S ratio decreased significantly after red ginseng intake. |
ADP, adenosine diphosphate; ADAS, Alzheimer's Disease Assessment Scale; ALT, alanine aminotransferase; APTT, activated partial thromboplastin time; AST, aspartate aminotransferase; BCAA, branched-chain amino acid; CAT, catalase; CDR, clinical dementia rating; CK, creatine kinase; DHEA, dehydroepiandrosterone; GOT, glutamic oxaloacetic transaminase; GPX, glutathione peroxidase; γ-GTP, γ-glutamyl transpeptidase; IL, interleukin; LDL, low-density lipoprotein; MDA, malondialdehyde; NK, natural killer; PT, prothrombin time; SOD, superoxide dismutase.
A randomized, double-blind, and placebo-controlled trial.
Effects of ginseng on drug-metabolizing enzymes and drug delivery systems
| Samples | Metabolisms | Transporters | References | |
|---|---|---|---|---|
| Ginsenoside Rd | CYP3A4 (↓), CYP2D6 (↓), CYP2C19 (↓), CYP2C9 (↓) | |||
| Ginsenoside Rg3 | UGT1A7, UGT1A8, UGT2B7, UGT2B15: (↓) | |||
| Ginsenosides Rc and Rf | CYP2C9 (↑), CYP3A4 (↑) | |||
| Ginsenoside F1 | CYP3A4 (↓), | P-gp (-) | ||
| Compound K | CYP2C9 (↓) | |||
| PPD and PPT | CYP2C9 (↓), CYP3A4 (↓) | |||
| Ginsenoside Rh2 (S) | CYP2A6 (↓), CYP2C9 (↓), CYP3A4 (↓) | P-gp (↓) | ||
| Red ginseng extract (Korea Ginseng Corporation) | CYP2C19 (-), CYP2D6 (-), CYP1A2 (↓), CYP2C9 (↓), CYP3A4 (↓) | P-gp (-) |
H, human liver microsome; R, rat liver microsome; (-), no effects; (↓), inhibition; (↑), stimulation.